Syndax Pharmaceuticals Inc Quarterly Operating Income (Loss) in USD from Q1 2015 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Syndax Pharmaceuticals Inc quarterly/annual Operating Income (Loss) history and growth rate from Q1 2015 to Q3 2024.
  • Syndax Pharmaceuticals Inc Operating Income (Loss) for the quarter ending September 30, 2024 was -$89.6M, a 59% decline year-over-year.
  • Syndax Pharmaceuticals Inc Operating Income (Loss) for the twelve months ending September 30, 2024 was -$321M, a 65.5% decline year-over-year.
  • Syndax Pharmaceuticals Inc annual Operating Income (Loss) for 2023 was -$230M, a 51.5% decline from 2022.
  • Syndax Pharmaceuticals Inc annual Operating Income (Loss) for 2022 was -$152M, a 679% decline from 2021.
  • Syndax Pharmaceuticals Inc annual Operating Income (Loss) for 2021 was $26.2M.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$321M -$89.6M -$33.2M -59% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-05
Q2 2024 -$288M -$74.2M -$24.5M -49.4% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 -$263M -$79.5M -$33.5M -72.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 -$230M -$77.9M -$35.9M -85.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-27
Q3 2023 -$194M -$56.4M -$21.2M -60.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 -$173M -$49.7M -$12M -31.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 -$161M -$46M -$9.16M -24.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 -$152M -$42M -$138M -144% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-27
Q3 2022 -$14M -$35.1M -$15.1M -75.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $1.14M -$37.7M -$15.4M -68.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 $16.5M -$36.9M -$9.7M -35.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 $26.2M $95.7M +$116M Oct 1, 2021 Dec 31, 2021 10-K 2024-02-27
Q3 2021 -$89.4M -$20M -$179K -0.9% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$89.2M -$22.3M -$5.72M -34.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 -$83.5M -$27.2M -$12.1M -79.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 -$71.4M -$19.9M -$5.66M -39.8% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-12
Q3 2020 -$65.8M -$19.9M -$6.7M -51% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$59.1M -$16.6M -$1.24M -8.04% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 -$57.8M -$15.1M -$289K -1.95% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-11
Q4 2019 -$57.5M -$14.2M +$5.13M +26.5% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-12
Q3 2019 -$62.7M -$13.1M +$4.69M +26.3% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-12
Q2 2019 -$67.4M -$15.4M +$3.58M +18.9% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-12
Q1 2019 -$70.9M -$14.8M +$4.94M +25% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-12
Q4 2018 -$75.9M -$19.3M +$156K +0.8% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-05
Q3 2018 -$76M -$17.8M -$2.4M -15.5% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-05
Q2 2018 -$73.6M -$19M -$5.11M -36.9% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-05
Q1 2018 -$68.5M -$19.8M -$6.57M -49.9% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-05
Q4 2017 -$62M -$19.5M -$8.35M -74.9% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-07
Q3 2017 -$53.6M -$15.4M -$208K -1.37% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-07
Q2 2017 -$53.4M -$13.8M -$5.21M -60.3% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-07
Q1 2017 -$48.2M -$13.2M -$4.42M -50.5% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-07
Q4 2016 -$43.8M -$11.1M -$6.46M -138% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-08
Q3 2016 -$37.3M -$15.2M -$9.38M -160% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-08
Q2 2016 -$27.9M -$8.63M -$3.09M -55.8% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-08
Q1 2016 -$24.8M -$8.75M -$4.32M -97.4% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-08
Q4 2015 -$20.5M -$4.68M Oct 1, 2015 Dec 31, 2015 10-K 2017-03-14
Q3 2015 -$5.86M Jul 1, 2015 Sep 30, 2015 10-K 2017-03-14
Q2 2015 -$5.54M Apr 1, 2015 Jun 30, 2015 10-K 2017-03-14
Q1 2015 -$4.43M Jan 1, 2015 Mar 31, 2015 10-K 2017-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.